Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.

Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.

Abstract: Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Abstract: An improved method for suppressing xenograft rejection in a host subject is disclosed. The method includes administering an immunosuppressant drug, where the drug or the amount of drug administered is, by itself, ineffective to suppress xenograft rejection. Effective xenograft suppression is achieved by also administering an ethanolic extract of Triterygium wilfordii or a purified triptolide component thereof.

Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.

Abstract: Disclosed are methods to inhibit mammalian skin cell proliferation and, in particular, human keratinocyte proliferation by the topical administration of neutral gallium complexes.

Abstract: The invention provides a method for treating fungal dermatitis comprising administering an effective amount of 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno?2,3-b!?1,5!benzodiazepine to a patient in need thereof.

Abstract: The invention relates to a phytotherapeutic agent for the treatment of skin lesions and morbid skin changes. In particular, it should be suitable for functioning as an effective therapeutic agent for the treatment of herpes simplex without significant side effects.The phytotherapeutic agent consists of an extract of components extractable from sage, (Salvia officinalis), ribwort plantain (Plantago lanceolata), greater plantain (Plantago major) and mistletoe (Viscum album).

Abstract: A composition and method for treatment of skin. The composition comprises a pharmaceutically acceptable carrier containing a bilayer component having one or more polar terminus groups and one or more non-polar terminus groups separated from said polar terminus groups capable of penetrating the outer surface of the skin to form an aligned bilayer within the stratum corneum. The bilayer assists in the formation of bilayer lamellae that is believed to replicate the bilayer lamellae present in healthy skin. The composition is topically applied to the skin as often as is required.

Abstract: An agent for treating a skin disease selected from the group consisting of a contact dermatitis treating agent, a xerosis senilis treating agent, an asteatosis treating agent, a housewives eczema treating agent, a keratosis treating agent, an eczema chronicum treating agent, a miliaria treating agent and a diaper rash treating agent, which contains hyaluronic acid and/or its salt having an average molecular weight of from 800,000 to 4,000,000, as an active ingredient.

Abstract: The invention relates to the use of cucurbitine or extracts of Cucurbitaceae pips for the preparation of a cosmetic or pharmaceutical, in particular dermatological, composition having antiallergic activity, or for the preparation of cosmetic or pharmaceutical compositions having a reduced risk of being allergenic.

Abstract: Cosmetic and/or dermatological active compound combinations comprisinga) an active amount of biotin and/or biotin esters,b) an active amount of one or more .alpha.-hydroxycarboxylic acids of the formulaR'(R")(OH)C COOHand/or an active amount of one or more .alpha.-ketocarboxylic acids of the formulaR'C(O) COOHor their physiologically acceptable salts or esters wherein R' and R" represent H-; branched or unbranched C.sub.1-25 -alkyl- or C.sub.1-25 -alkyl-substituted by one or more carboxyl groups and/or hydroxyl groups and/or a aldehyde groups and/or oxo groups (keto groups); phenyl- or phenyl substituted by one or more carboxyl groups and/or hydroxyl groups and/or branched and/or unbranched C.sub.1-25 -alkyl groups; or wherein the .alpha.-carbon atom of the .alpha.

Abstract: Topical compositions for the treatment of corns, calluses and warts comprising a benzenediol or a substituted 1,2-benzenediol and a pharmaceutically acceptable carrier, are described.

Abstract: The present invention relates to the preparation and use of compositions for the treatment of skin disorders such as psoriasis, eczema and lichen planus, as well as for the promotion of good health and the alleviation of stress. The compositions are based on extracts from the plants Melia azadirachta and/or Centratherum anthelminthicum. A variety of other herbal extracts may be included, and the compositions may take the form of a cream or ointment based on ghee, or they may be in a powdered form of suitable for preparing decoctions in hot water.

Abstract: Di(aromatic) compounds corresponding to the following formula: ##STR1## in which: Ar represents either ##STR2## n=1 or 2 or: ##STR3## X represents a divalent radical, Z represents O, S or a divalent radical, and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 represent a hydrogen atom or various organic radicals, and the salts of the compounds of formula (I) when R.sub.1 is a carboxylic acid function.Use in human and veterinary medicine and in cosmetics.

Abstract: Psoriasis, seborrheic dermatitis and eczema are treated by oral administration of inorganic nickel compound(s), with or without inorganic bromide(s). In an especially preferred embodiment, the nickel compound used to treat these diseases is NiBr.sub.2.

Abstract: Typical treatment of psoriasis and other diseases of skin cell hyperproliferation using pharmaceutical compositions containing mono-, di, and tri-phosphate esters of antiproliferative nucleoside analogs and related analogs, DNA chain-terminating dideoxynucleosides and other nucleoside analogs. The useful phosphate esters include phosphoramidates and phosphothiorates, as well as polyphosphates having C and S bridging atoms.

Abstract: The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.

Abstract: The present invention comprises methods and compositions for topically treating keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.

Abstract: Dermatological compositions comprising nitrous oxide and at least one essential fatty acid or lower alkyl ester thereof in a dermatologically acceptable carrier medium is useful in the treatment of a variety of skin, muscle and joint disorders including psoriasis, shingles, fever blisters, chicken pox, ache, chilblains, eczema, chloasmas, alopecia, dermatitis, ringworm and burn wounds. The composition preferably also includes additional ingredients selected from coal tar, collagen, nicotinamide, nicotinic acid, lanolin, vitamin E, methyl salicylate, arnica, and H.sub.1 -antagonist antihistamines or combinations thereof.

Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.

Abstract: The invention relates to the use of an extract of prunella or at least one prunella saponin. This extract or this saponin is used for the preparation of a cosmetic or pharmaceutical and/or dermatological composition. Said composition makes it possible to regulate the renewal and differentiation of the keratinocytes and has an anti-aging activity, an anti-inflammatory activity, especially in inflammations caused by ultraviolet radiation, or an anti-allergic or anti-free-radical activity. It also enables the epidermis of normal skin to be kept in good condition, especially by maintaining the functional role of the skin, in particular as a protective barrier, and makes it possible to prevent or treat dry skin, especially ichthyotic skin, and to treat psoriasis.

Abstract: Methods and pharmaceutical compositions for use in inhibiting calmodulin activity in a patient are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient in need of treatment of a non-estrogen dependent condition.

Abstract: Methods and compositions are provided for the treatment of a host with a cellular proliferative disease, particularly a neoplasia. In the subject methods, a pharmaceutically acceptable, substantially anhydrous, injectable semi-solid composition which acts as a depot for a cytostatic agent, is administered to a lesion of the disease, particularly intralesionally. The subject compositions comprise a water immiscible, fatty acid ester matrix and a cytostatic agent.

Abstract: Novel pharmaceutically/cosmetically-active adamantyl-substituted polycyclic acetylene compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(f): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Abstract: Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl; are provided.

Abstract: Low pH acidic compositions for uses related generally to chemical, pharmaceutical and cosmetic agents and more particularly, but not limited to, used as bactericides, fungicides, germicides and virucides; all having pH values of less than about 2.0 in their final form. These low pH acidic compositions generally comprise two phases in solution. Phase I comprises from about 2 to about 98 weight percent of varying percentages of several chemical, pharmaceutical and cosmetic substances.Phase II comprises from about 2 to about 99 weight percent of an active aqueous acidic component having a pH value of less than about 1.

Abstract: Pharmaceutical for the treatment of skin disordersA compound of the formula I or II ##STR1## and physiologically tolerable salts of compound of the formula II are suitable for treatment of psoriasis.

Abstract: Dermatological compositions having an effective content of cis-urocaninic acid and/or its derivatives, the process for the produktion of such compositions and the method of use of dermatological compositions having a content of cis-urocaninic acid for the treatment and the prophylaxis of inflammatory dermatoses and for the care and restoration of senstive and stressed skin.

Abstract: A mixture of .beta.-sitosterol glucoside and .beta.-sitosterol is administered to persons for the modulation or control of immune responses. The two compounds may be added in admixture or sequentially. Diseases such as viral and bacterial infections, autoimmune diseases, psoriasis, ezcema, asthma, cancer may be treated.

Abstract: An external skin treatment composition containing (I) vitamin A (retinol) and (II) as a stabilizer, a chelating agent/a polysaccharide, an oil, polyethylene (propylene) glycol, a hydroxy carboxylate, a neutral amino acid salt, an oil-soluble antioxidant/EDTA/a benzophenone compound, an oil-soluble antioxidant/an acid/a benzophenone compound, an inclusion compound of cyclodextrin including an antioxidant and/or an ultraviolet absorber, butanediol and/or an oil-soluble antioxidant, a water-soluble benzophenone compound, a basic amino acid and the salt thereof, an acidic amino acid and the salt thereof, a polar oil, a water-swellable clay mineral.

Abstract: Compounds of formula I ##STR1## and compounds of formula Ia ##STR2## and their physiologically tolerated salts, processes for their preparation and drugs and cosmetics prepared therefrom.

Abstract: New pharmaceutical compositions for topical use containing esters of .omega.-3 polyunsaturated acids having a high concentration have been obtained. Such formulations have been added with phenolic antioxidants and with adjuvants.The present formulations have been found clinically useful in the treatment of morbid affections, in particular in the treatment of psoriasis, phlebitis and the correlated pathologies.

Abstract: A process is provided which is suitable for the preparation of herbal compositions for the treatment of skin disorders such as eczema and psoriasis. The process comprises preparing an extract or extracts of herbs which provide an anti-inflammatory agent, an adrenocortical stimulant and a cortisol protecting agent by steam distillation and decoction and then treating the extracts to reduce the polysaccharide and/or sugar content. This is achieved by fermentation or enzymic action or by extraction with a solvent having a polarity in the range E.degree. 0.4 to 0.95 or by precipitation with an inorganic compound and/or colloid or by a combination of two or more of the above. As a final concentration step, the material is further purified by extraction with a solvent having a polarity in the range mentioned above. The reduction of the sugar/polysaccharide content greatly improves the handling characteristics of the extract which can be dried to a free flowing powder.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;are provided.

Abstract: Autoimmune diseases are controlled by the administration of non-methylene interrupted fatty acids of the formula ##STR1## in which R is alkyl or alkenyl. A preferred compound within the scope of this formula is 5,11,14-eicosatrienoic acid.

Abstract: The invention relates to a pharmaceutical preparation comprising as an active ingredient at least one rhamnolipid or a pharmaceutically acceptable salt thereof, and a carrier and/or diluent, preferably comprising a rhamnolipid of the general formula: ##STR1## wherein R.sub.1 =H, alpha-L-rhamnopyranosyl; ##STR2## R.sub.3 =(C.sub.5 -C.sub.20)-saturated, -mono- of poly-unsaturated alkyl; R.sub.4 =(C.sub.5 -C.sub.

Abstract: A composition for topical application to the skin for alleviation or prevention of dry flaky skin conditions, dandruff or acne comprising:(1) a glycosidase; and(2) a protease the components (1) and (2) being present simultaneously in the composition or being separately presented with indication for the application of component (1) before component (2) .

Abstract: A topical agent and method for the treatment and prevention of pseudofolliculitis barbae, related secondary bacterial infections and other skin conditions associated with shaving result from a combination of three ingredients, namely benzoyl peroxide, camphor oil and aloe vera present in 15:4:1 parts by volume of the composition, respectively.

Abstract: An antifungal agent for the treatment of skin disease such as athlete's foot, ringworm and tinea caused by dermatophytes, eczema, tinea or various fungi, which comprises a 100 weight % of detergent solution including 0.01-40 weight % of sodium hypochlorite, 0.01-30 weight % of sodium sulfite, 0.01-40 weight % of sodium nitrite, 0.01-40 weight % of sodium chlorate, 0.01-40 weight % of potassium chlorate, 0.001-35 weight % of hydrogen peroxide, 0.01-40 weight % of ozone water, 0.01-40 weight % of sodium nitrite, 0.01-40 weight % of potassium nitrite, 0.001-1 weight % of nonionic surface active agent and 1-90 weight % of water.It is characterized in that trichophyton, eczema or various fungi in the dermis or deep layer are allured by oxygen contained in the antifungal agent to or near the surface of the skin for easy sterilization by oxidation, reduction, bleaching and fungicidal activity.A ligand agent is also efficacious for the treatment of a burn of the skin and of stiffness in the shoulder.

Abstract: The invention provides a composition for topical application to the skin comprising a mixture of Panthenol (B.sub.5), Cod Liver Oil, Alpha Tocopherol Acetate, Arginine, Isoleucine, Leucine, Methionine, Phenylalanine, Threonine, and Valine in admixture with a suitable carrier. These compositions are particularly useful for the treatment of burns, cuts, abrasions, insect bites, inflammation from sun and wind exposure, dry skin, psoriasis, seborrheic dermatitis, and eczema.

Abstract: Methods and products for promoting hair growth, preventing or minimizing hair loss, enhancing or restoring hair color or remelanization and treating other hair and skin afflictions are disclosed. The methods includes topical application of the products to the skin or hair follicles being treated. The product includes as an essential component a treatment agent in an amount effective for treating the affliction and selected from the class of chemicals consisting of anol, anethole, analogs of the above, polymers of the above and mixtures thereof. Various combinations of these chemicals may be found in herb families including umbelliferae, magnoliaceae, labiatae and rutaceae. The invention preferably contemplates selecting the treatment agent from the class of herbs consisting of Foeniculum vulgares (fennel seed), Pimpinella anisum (anise), Carum carvi (caraway seeds) and mixtures of the above herbs with each other and/or with other herbs.

Abstract: A dermatological pharmaceutical composition for stimulating hair growth and for the treatment of conditions of the skin selected from the group consisting of(a) benign moles, papillomas and seborrheic keratoses;(b) unsightly freckles, pimples and blemishes;(c) stasis dermatitis;(d) dermal ulcers; and(e) fungal nail infections; and(f) gingival and mucous membrane inflammations;the composition comprising an effective amount of tannic acid, a debriding agent and a pharmaceutically acceptable carrier therefore.

Abstract: Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.

Abstract: Solution comprising a mixture of aluminum acetate topical solution and glycerin useful as a skin moisturizer and/or a food particulate repellant for preventing chewed food particles from sticking to the teeth. When combined with a flavoring agent, the solution of aluminum acetate topical solution and glycerin is also effective as a saliva substitute for relieving the symptoms of xerostomia or "dry mouth syndrome.

Abstract: A therapeutic agent for allergic diseases containing as an active ingredient an extract of Acanthopanax senticosus Harms. It became possible to provide a medicine enabling allergic diseases to be treated without causing almost no side effects.

Abstract: The use of essential fatty acids having 18-20 carbon atoms for producing a pharmaceutical preparation for the treatment of infantile seborrhoeic eczema or asteatotic eczema.

Abstract: A method of treating hyperproliferative skin disease in a mammal with substituted spiro pyridine derivatives is disclosed. The compounds may be administered topically or by other conventional routes of administration.

Abstract: A method is provided for treating dermatological conditions by binding and blocking 5-a-dihydrotestosterone receptors comprising applying to the skin an effective amount of composition comprising:(a) from about 0.1% to about 2.0% by weight of mucopolysaccharides free of proteins and having a pH ranging from about 5 to 7.5 in aqueous solution, a rotary power between about to +15, and a sulfur content greater than 6%;(b) from about 1% to about 3% by weight of an aqueous extract of human umbilical cord free from sulfur and having a DH of from about 5 to about 7, a viscosity of 30.degree. C. of from 10 to 25 centistokes, a hyaluronic acid titre of from about 500 to about 700 mg/dl, and an ash content of less than about 0.5%;(c) from about 0.05 to about 0.08% by weight of tetrahydrofurfuryl nicotinate; and(d) pharmaceutically and cosmetically acceptable vehicles and excipients.